Premium
Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody
Author(s) -
Wang Chao,
Sun Wujin,
Wright Grace,
Wang Andrew Z.,
Gu Zhen
Publication year - 2016
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201506312
Subject(s) - cpg oligodeoxynucleotide , cpg site , immunotherapy , cancer , inflammation , immune system , antibody , cancer research , cancer immunotherapy , immunology , materials science , medicine , biology , biochemistry , dna methylation , gene expression , gene
Inflammation‐triggered combination delivery of anti‐PD‐1 antibody and CpG oligodeoxynucleotides (CpG ODNs) has been demonstrated to prevent cancer relapse utilizing postsurgical inflammatory response. The controlled release of anti‐PD1 and CpG ODN by CpG DNA‐based "nano‐cocoons" can induce considerable immune response, which in turn significantly prolongs the survival time of mice.